DOP2010000114A - Producto de dispersion solida que contiene un compuesto a base de n-aril urea - Google Patents
Producto de dispersion solida que contiene un compuesto a base de n-aril ureaInfo
- Publication number
- DOP2010000114A DOP2010000114A DO2010000114A DO2010000114A DOP2010000114A DO P2010000114 A DOP2010000114 A DO P2010000114A DO 2010000114 A DO2010000114 A DO 2010000114A DO 2010000114 A DO2010000114 A DO 2010000114A DO P2010000114 A DOP2010000114 A DO P2010000114A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- solid dispersion
- urea
- aril
- based compound
- product containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un producto que comprende al menos un agente farmaceuticamente activo a base de N-aril urea o un agente de estructura relacionada que es obtenido mediante a) la preparación de una mezcla liquida que contiene el al menos un agente activo, el al menos un agente formador de matriz aceptable para use farmaceutico, el al menos un tensioactivo aceptable para use farmaceutico y el al menos un solvente, y b) la eliminación del o de los solventes de la mezcla liquida para obtener el producto de dispersión sólida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99961307P | 2007-10-19 | 2007-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2010000114A true DOP2010000114A (es) | 2010-05-15 |
Family
ID=40089072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2010000114A DOP2010000114A (es) | 2007-10-19 | 2010-04-16 | Producto de dispersion solida que contiene un compuesto a base de n-aril urea |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090143423A1 (es) |
EP (1) | EP2197426A2 (es) |
JP (1) | JP2011500647A (es) |
KR (1) | KR20100090689A (es) |
CN (1) | CN101827585A (es) |
AR (1) | AR068916A1 (es) |
AU (1) | AU2008313620A1 (es) |
BR (1) | BRPI0818339A2 (es) |
CA (1) | CA2699335A1 (es) |
CL (1) | CL2008003092A1 (es) |
CO (1) | CO6270303A2 (es) |
CR (1) | CR11441A (es) |
DO (1) | DOP2010000114A (es) |
EC (1) | ECSP10010184A (es) |
GT (1) | GT201000095A (es) |
MX (1) | MX2010004292A (es) |
PE (1) | PE20091041A1 (es) |
RU (1) | RU2010119924A (es) |
TW (1) | TW200922549A (es) |
UA (1) | UA100866C2 (es) |
UY (1) | UY31406A1 (es) |
WO (1) | WO2009050289A2 (es) |
ZA (1) | ZA201002130B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8604053B2 (en) * | 2008-10-17 | 2013-12-10 | Abbvie Inc. | TRPV1 antagonists |
JP2012505908A (ja) * | 2008-10-17 | 2012-03-08 | アボット・ラボラトリーズ | Trpv1アンタゴニスト |
US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
CN102573755A (zh) * | 2009-09-18 | 2012-07-11 | 巴斯夫欧洲公司 | 制备具有低水溶性的物质的制剂的方法 |
ES2598235T3 (es) * | 2010-12-23 | 2017-01-26 | AbbVie Deutschland GmbH & Co. KG | Formulaciones de retardo sólidas basadas en dispersiones sólidas |
CN103391770A (zh) | 2011-01-10 | 2013-11-13 | 细胞基因公司 | 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型 |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
MX2014008008A (es) * | 2011-12-29 | 2014-08-21 | Abbvie Inc | Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c. |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
DK2950786T3 (da) | 2013-01-31 | 2020-02-17 | Gilead Pharmasset Llc | Kombinationsformulering af to antivirale forbindelser |
KR20150129005A (ko) | 2013-03-15 | 2015-11-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 무정형 상태의 hcv 억제제의 고체 경구 투여 제형 |
CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
ES2792503T3 (es) | 2013-08-27 | 2020-11-11 | Gilead Pharmasset Llc | Formulación combinada de dos compuestos antivirales |
CA2948221C (en) | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
WO2015177204A1 (en) * | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
EP3145503A1 (en) | 2014-05-20 | 2017-03-29 | LTS Lohmann Therapie-Systeme AG | Method for adjusting the release of active agent in a transdermal delivery system |
EP3393462B8 (en) * | 2015-12-22 | 2023-06-21 | Arizona Board of Regents on behalf of the University of Arizona | Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia |
CN112955130A (zh) * | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
JP6830569B1 (ja) | 2019-08-23 | 2021-02-17 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362878A (en) * | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
WO1993024458A1 (en) * | 1992-05-28 | 1993-12-09 | Pfizer Inc. | New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat) |
CA2302735A1 (en) * | 1998-07-14 | 2000-01-27 | Em Industries, Inc. | Microdisperse drug delivery systems |
US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
TWI389688B (zh) * | 2004-06-08 | 2013-03-21 | Vertex Pharma | Vx-950之形態與調配物及其製備方法與用途 |
JP5128948B2 (ja) * | 2004-08-27 | 2013-01-23 | ニッポネックス インコーポレイテッド | 癌の治療のための新規な薬剤組成物 |
MX2007012947A (es) * | 2005-04-18 | 2008-04-09 | Rubicon Res Pvt Ltd | Composiciones biomejoradas. |
KR100715355B1 (ko) * | 2005-09-30 | 2007-05-07 | 주식회사유한양행 | 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법 |
US20070104780A1 (en) * | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
WO2007066189A2 (en) * | 2005-12-09 | 2007-06-14 | Pfizer Products Inc. | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
US7745448B2 (en) * | 2005-12-28 | 2010-06-29 | Abbott Laboratories Inc. | Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate |
NZ569700A (en) * | 2006-02-09 | 2011-09-30 | Merck Sharp & Dohme | Polymer formulations of CETP inhibitors |
-
2008
- 2008-10-17 JP JP2010529406A patent/JP2011500647A/ja active Pending
- 2008-10-17 AU AU2008313620A patent/AU2008313620A1/en not_active Abandoned
- 2008-10-17 RU RU2010119924/15A patent/RU2010119924A/ru not_active Application Discontinuation
- 2008-10-17 UA UAA201006030A patent/UA100866C2/ru unknown
- 2008-10-17 CA CA2699335A patent/CA2699335A1/en not_active Abandoned
- 2008-10-17 WO PCT/EP2008/064073 patent/WO2009050289A2/en active Application Filing
- 2008-10-17 PE PE2008001785A patent/PE20091041A1/es not_active Application Discontinuation
- 2008-10-17 TW TW097140229A patent/TW200922549A/zh unknown
- 2008-10-17 CN CN200880112161A patent/CN101827585A/zh active Pending
- 2008-10-17 AR ARP080104542A patent/AR068916A1/es not_active Application Discontinuation
- 2008-10-17 BR BRPI0818339 patent/BRPI0818339A2/pt not_active IP Right Cessation
- 2008-10-17 UY UY31406A patent/UY31406A1/es not_active Application Discontinuation
- 2008-10-17 US US12/253,499 patent/US20090143423A1/en not_active Abandoned
- 2008-10-17 CL CL2008003092A patent/CL2008003092A1/es unknown
- 2008-10-17 MX MX2010004292A patent/MX2010004292A/es not_active Application Discontinuation
- 2008-10-17 EP EP08840773A patent/EP2197426A2/en not_active Withdrawn
- 2008-10-17 KR KR1020107010874A patent/KR20100090689A/ko not_active Application Discontinuation
-
2010
- 2010-03-25 ZA ZA2010/02130A patent/ZA201002130B/en unknown
- 2010-04-15 GT GT201000095A patent/GT201000095A/es unknown
- 2010-04-16 DO DO2010000114A patent/DOP2010000114A/es unknown
- 2010-04-27 CO CO10049270A patent/CO6270303A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010184A patent/ECSP10010184A/es unknown
- 2010-05-19 CR CR11441A patent/CR11441A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090143423A1 (en) | 2009-06-04 |
CR11441A (es) | 2010-10-25 |
GT201000095A (es) | 2012-04-03 |
MX2010004292A (es) | 2010-08-02 |
AU2008313620A1 (en) | 2009-04-23 |
EP2197426A2 (en) | 2010-06-23 |
WO2009050289A2 (en) | 2009-04-23 |
WO2009050289A3 (en) | 2010-03-25 |
CA2699335A1 (en) | 2009-04-23 |
TW200922549A (en) | 2009-06-01 |
ZA201002130B (en) | 2011-11-30 |
BRPI0818339A2 (pt) | 2015-04-22 |
JP2011500647A (ja) | 2011-01-06 |
KR20100090689A (ko) | 2010-08-16 |
UA100866C2 (ru) | 2013-02-11 |
ECSP10010184A (es) | 2010-06-29 |
CN101827585A (zh) | 2010-09-08 |
CL2008003092A1 (es) | 2009-11-27 |
PE20091041A1 (es) | 2009-08-22 |
CO6270303A2 (es) | 2011-04-20 |
RU2010119924A (ru) | 2011-11-27 |
UY31406A1 (es) | 2009-05-29 |
AR068916A1 (es) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2010000114A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
DOP2010000117A (es) | Producto de dispersion solida de drogas basadas en n-aril urea | |
AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
CL2011000653A1 (es) | Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer. | |
PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
AR051969A1 (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central | |
PE20060130A1 (es) | Aparato para producir un producto farmaceutico | |
AR053517A1 (es) | Proceso para la preparacion de compuestos de tetrazolilo, uso de los mismos en el tratamiento de enfermedades circulatorias y formulaciones farmaceuticas que los contienen. | |
CU20060153A7 (es) | Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen | |
CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
CL2013000488A1 (es) | Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas. | |
UY29701A1 (es) | Formulaciones líquidas para la administración controlada de derivados de bencisoxazol | |
CL2013003161A1 (es) | Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion. | |
AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
CL2007001981A1 (es) | Composicion que comprende al menos un principio activo agroquimico del grupo de los piretroides, al menos un tensioactivo, y al menos un disolvente no miscible en agua; procedimiento para la lucha contra las plagas animales; y su uso. | |
CL2011001207A1 (es) | Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos. | |
UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
AR093922A1 (es) | Composicion farmaceutica que contiene telmisartan | |
AR105503A1 (es) | Concentrado que contiene alprostadil | |
AR078167A1 (es) | Dispersion solida que comprende un agente anti-vih | |
CO6270249A2 (es) | Fibra, pelicula o espuma que comprende un plastificador y un gel ligado a arcilla cargado y metodos para su produccion | |
CO2022004312A2 (es) | Formulación de mezclas insecticidas que comprenden solventes de glicol éter | |
TH104743B (th) | ผลิตภัณฑ์แพร่กระจายแข็งที่มีสารประกอบ n-อะริล ยูเรีย | |
CL2009000574A1 (es) | Formulacion farmaceutica que comprende como principio activo a compuestos derivados de pirona-indol, agonista/antagonista mt1 y mt2; y su uso en el tratamiento de diabetes tipo 2, problemas del snc, cardiovasculares, entre otros (divisional de solicitud 447-07). |